Medicure (CVE:MPH) Reaches New 12-Month High – Here’s What Happened

Medicure Inc. (CVE:MPH) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as C$2.60 and last traded at C$2.55, with a volume of 10238 shares. The stock had previously closed at C$2.55.

Medicure Trading Up 0.4%

The company has a debt-to-equity ratio of 6.02, a quick ratio of 1.28 and a current ratio of 0.97. The firm has a market cap of C$26.72 million, a P/E ratio of -3.56 and a beta of 0.44. The firm has a 50 day simple moving average of C$1.29 and a 200 day simple moving average of C$1.18.

Medicure Company Profile

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.